Breaking News Headlines Today | Ground News

See every side of every news story

Pharmaceutical Business Review image

News from Pharmaceutical Business review

Ground News rates Pharmaceutical Business Review’s media bias as unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

Pharmaceutical Business Review’s factuality rating is Unknown. Ground News calculates this rating using a combination of the fact and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about Pharmaceutical Business Review

Where is Pharmaceutical Business Review located?Pharmaceutical Business Review's Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top Pharmaceutical Business Review News

Oral Drug Wins FDA Approval for Chronic Hives

Chatham, Virginia · Chatham

Oral Drug Wins FDA Approval for Chronic Hives

66% Center coverage: 26 sources

(MedPage Today) -- The FDA approved oral remibrutinib (Rhapsido) as a second-line treatment for chronic spontaneous urticaria (CSU), or chronic hives, Novartis announced on Tuesday. Indicated for adults with stubborn symptoms despite the use of...See the Story

Lilly's Kisunla (Donanemab) Receives Marketing Authorization by European Commission for the Treatment of Early Symptomatic Alzheimer's Disease

Alzheimer's Disease · Belgium

Lilly's Kisunla (Donanemab) Receives Marketing Authorization by European Commission for the Treatment of Early Symptomatic Alzheimer's Disease

80% Center coverage: 26 sources

Approved for earliest symptomatic stages of disease, demonstrating significant slowing of cognitive and functional decline See the Story

JnJ Tremfya Gets USFDA Approval for Subcutaneous Induction in Adults with Ulcerative Colitis

Johnson & Johnson · United States

JnJ Tremfya Gets USFDA Approval for Subcutaneous Induction in Adults with Ulcerative Colitis

75% Center coverage: 12 sources

Horsham: Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved a subcutaneous (SC) induction regimen of TREMFYA (guselkumab) for the treatment of adults with...See the Story

Breaking News Topics Related to Pharmaceutical Business Review